Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Medtronic
Dow
Moodys
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GADOFOSVESET TRISODIUM

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Gadofosveset Trisodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01135316 Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR Completed Lantheus Medical Imaging N/A 2009-10-01 Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months.
NCT01165892 Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) Completed Lantheus Medical Imaging N/A 2011-07-01 The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI).
NCT01165892 Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) Completed Washington University School of Medicine N/A 2011-07-01 The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI).
NCT01655043 Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI Completed Astellas Pharma Global Development, Inc. Phase 2 2012-09-01 Coronary artery disease (CAD, coronary heart disease) is the leading cause of death in the U.S., causing 1 in 5 deaths in 2005. The current method for diagnosing coronary artery disease that is considered most accurate is coronary angiography however it involves risk and radiation. Alternatively nuclear imaging test and MRI stress test only permits the semi qualitative analysis of the myocardial perfusion images. In this proposal the investigators will develop a means to calculate Coronary Flow Reserve (CFR) using the MRI. the investigators approach has the potential to reduce mortality from myocardial infarction by effecting a change in the patient management paradigm. Absolute quantification of myocardial perfusion will detect coronary stenosis and CAD in patients with more accuracy than the semi-quantitative or qualitative analysis of perfusion images. Measurement of Coronary Flow Reserve is important for the following reasons: decrease of coronary flow reserve has been identified as a first effect of CAD; it provides an objective measure of treatment efficacy. The purpose of this study is to compare images from nuclear stress test and/or coronary angiography with Magnetic Resonance Imaging (MRI) that will evaluate subjects with coronary artery disease calculating myocardial blood flow using a novel MRI technique combined to an extracellular Gadolinium-based contrast agent and stressor agent
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gadofosveset Trisodium

Condition Name

Condition Name for Gadofosveset Trisodium
Intervention Trials
Myocardial Ischemia 1
Rectal Neoplasms 1
Magnetic Resonance Imaging 1
Pulmonary Embolism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Gadofosveset Trisodium
Intervention Trials
Ischemia 1
Heart Diseases 1
Coronary Artery Disease 1
Heart Defects, Congenital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Gadofosveset Trisodium

Trials by Country

Trials by Country for Gadofosveset Trisodium
Location Trials
Netherlands 5
United States 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Gadofosveset Trisodium
Location Trials
California 1
Illinois 1
North Carolina 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Gadofosveset Trisodium

Clinical Trial Phase

Clinical Trial Phase for Gadofosveset Trisodium
Clinical Trial Phase Trials
Phase 4 2
Phase 2 1
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Gadofosveset Trisodium
Clinical Trial Phase Trials
Completed 3
Recruiting 1
Suspended 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Gadofosveset Trisodium

Sponsor Name

Sponsor Name for Gadofosveset Trisodium
Sponsor Trials
Maastricht University Medical Center 2
Lantheus Medical Imaging 2
Paul Finn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Gadofosveset Trisodium
Sponsor Trials
Other 6
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Colorcon
AstraZeneca
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.